Summary

Results of the PARAMETER study demonstrated that the angiotensin receptor neprilysin inhibitor LCZ696 reduced central aortic systolic and pulse pressure more effectively than olmesartan in older patients with systolic hypertension and arterial stiffness. Both treatments were safe and well tolerated without significantly variability in key safety parameters between the groups.